Intraurethral/Intravaginal 2940 nm Erbium Laser Treatment For Stress Urinary Incontinence

Pilot Single-masked, Randomized, 3-arm Parallel Study Assessing the Tolerability, Safety and Efficacy of Intraurethral/Intravaginal 2940 nm Er:YAG Laser Treatment For Stress Urinary Incontinence

Primary objective is to assess the tolerability and safety of the intraurethral 2940nm Er:YAG laser technique in combination with intravaginal 2940nm Er:YAG laser method for the treatment of stress urinary incontinence.

Study Overview

• Status: Unknown
• Conditions: Stress Urinary Incontinence
• Intervention / Treatment: Device: Sham Fotona SP Dynamis; Device: Intravaginal Fotona SP Dynamis; Device: Intraurethral Fotona SP Dynamis

Detailed Description

This study is a prospective, randomized, 3-arm parallel pilot study. Study subjects will be women currently experiencing female stress urinary incontinence (SUI) and stress-predominant mixed urinary incontinence (SMUI) with a degree of intrinsic sphincter deficiency for a minimum duration of 6 months prior to enrolment. Diagnosis of SUI with a degree of intrinsic sphincter deficiency will be performed using urodynamic and clinical assessment.

Subjects will undergo sham, intravaginal, and the combination of intravaginal and intraurethral treatment with the 2940 nm Er:yttrium aluminum garnet Er:YAG laser at two time points, 4 weeks apart. Primary objective is to assess the tolerability and safety of the intraurethral 2940nm Er:YAG laser technique in combination with intravaginal 2940nm Er:YAG laser method for the treatment of stress urinary incontinence through 6 months follow-up and extend to 12 months follow-up.

Secondary objective is to assess the effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments using subjective and objective measures, as well as improvement in quality of life through 6 months follow-up and extend to 12 months follow-up.

• Study Type: Interventional
• Enrollment (Anticipated): 55
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Branka Korosec, PhD; Phone Number: +386015009185; Email: branka.korosec@fotona.com

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5T 2S8
      • Recruiting
      • University Urology Associates
      • Contact: Iris Chan; Phone Number: 5033 416 603 5800; Email: Iris.Chan2@uhn.ca
      • Contact: Dean S. Elterman, MD; Phone Number: 5033 416 603 5800; Email: dean.elterman@uhn.ca
  • Quebec
    • Sherbrooke, Quebec, Canada, J1L 1C6
      • Recruiting
      • Exgogenia, Institute of Anti-Aging and Regenerative Medicine
      • Contact: Le Mai Tu, PhD; Phone Number: 1-819-791-8866; Email: Le.mai.tu@usherbrooke.ca
      • Contact: Helen Lavoie; Phone Number: 1-819-791-8866; Email: hlavoie7@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female between 18 and 80 years
• SUI or MUI with predominantly stress symptoms for more than 6 months
• Has failed 2 previous non-invasive therapies for three (3) months each (e.g. behavioural modification, electrical stimulation, pelvic muscle exercise, biofeedback, and/or drug therapy)
• Confirmed SUI through cough stress test or urodynamics
• Has at least one incontinence episode per 24 hour period measured over three days
• Valsalva leak-point pressure (VLPP) ≤100 cm H2O
• Has a baseline 24h pad weight test ≥ 10 gm
• Has maximum cystometric capacity ≥250 mL
• No pelvic surgery within last 6 months (including prolapse repair, subjects who have residual or recurrent SUI following colposuspension or a sling procedure may be included in the study if the procedure was conducted at least 6 months prior to screening /baseline visit)
• Willing to give informed consent and complete the follow up schedule

Exclusion Criteria:

• Active urinary tract or vaginal infection or other active infections of urinary tract or bladder (urethritis, cystitis or vaginitis)
• Has had three (3) or more cultured-proven bacterial urinary tract infection (UTI) in the last 12 months
• Clinical diagnosis of urge incontinence or urge predominant mixed incontinence
• Has detrusor overactivity on urodynamics
• postvoiding residual (PVR) > 100 ml
• Has had previous urethral surgery (i.e. fistula or diverticula)
• Grade 2 or higher Pelvic organ prolapse (POP) or Pelvic organ prolapse grade > 2 as defined by POP-Q and symptomatic
• Suffers from known polyuria (>3l/24h)
• Has a BMI ≤35 kg/m2
• Has unevaluated hematuria
• Has a neurogenic bladder
• Evidence of dysplasia in a Pap smear (done in the last 24 months)
• Tumours of the Urinary tract
• Previous radiation or brachytherapy to treat pelvic cancer
• Has uncontrolled diabetes
• Has active herpes genitalis
• Pregnancy, lactating, or not practicing adequate contraception and/or planning to get pregnant in the next 12 months
• Had a vaginal delivery within 6 months prior to the Screening/Baseline Visit
• Is currently participating in any other clinical trial, or has participated in another clinical trial within 3 months prior to the Screening/Baseline Visit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Sham Treatment; Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.	Device: Sham Fotona SP Dynamis; Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
Active Comparator: Intravaginal Treatment; Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.	Device: Intravaginal Fotona SP Dynamis; Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
Experimental: Intravaginal and intraurethral Treatment; Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.	Device: Intravaginal Fotona SP Dynamis; Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis; Device: Intraurethral Fotona SP Dynamis; Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerability of the 2940nm Er:YAG laser technique by VAS pain scale	The tolerability of intra-urethral/intravaginal Er:YAG laser treatment by VAS pain scale during procedure and by monitoring the use of pain relieving medication post treatment. The Visual Analog Scale for Pain (VAS) is a unidimensional measure of pain intensity, which has been widely used in diverse adult populations.	18 months
The Safety of intra-urethral/intravaginal Er:YAG laser procedure by recording the incidence and severity of complications	The Safety of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women, as assessed by recording the incidence and severity of complications	18 months
The Safety of intra-urethral/intravaginal Er:YAG laser procedure by recording the incidence of device related adverse events	The Safety of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women, as assessed by recording the incidence of device related adverse events	18 months
The Safety of intra-urethral/intravaginal Er:YAG laser procedure by measure uroflow and post void residual (PVR)	The Safety of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women, as assessed by measure uroflow and post void residual (PVR) 6 months after the 2ed treatment	18 months
The Safety of intra-urethral/intravaginal Er:YAG laser procedure by Questionnaire for voiding symptoms (based on IPSS)	The Safety of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women, as assessed by questionnaire for voiding symptoms (based on IPSS)	18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by recording 3-day voiding diary	The efficacy of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women by recording of improvement in daily number of incontinence episodes via 3-day voiding diary The 3-day voiding diary is a log used to record number of pads used, incontinence episodes, the activity in which the subject was engaged when the incontinence occurred, and micturitions.	18 months
The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by 24-Hour Pad-Weight Test	The 24-Hour Pad-Weight Test will be used to reflect everyday incontinence. This test, standardized by the International Continence Society, correlates well with UI symptoms, and has good reproducibility.	18 months
The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by ICIQ-UI short form questionnaire	The efficacy of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women reduction in SUI as measured by ICIQ-UI short form questionnaire. The ICIQ-UI Short Form Questionnaire provides a brief and robust measure to assess the impact of symptoms of incontinence on quality of life and outcome of treatment.	18 months
The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by recording patient global impression of improvement (PGI-I)	• The efficacy of intra-urethral/intravaginal Er:YAG laser procedure for the treatment of stress urinary incontinence in women by recording patient global impression of improvement (PGI-I). The Patient Global Impression of Improvement (PGI-I) Questionnaire is a global index that may be used to rate the response of a condition to a therapy (transition scale).	18 months

Collaborators and Investigators

• Sponsor: Fotona d.o.o.

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2018
• Primary Completion (Anticipated): December 4, 2021
• Study Completion (Anticipated): December 4, 2021

Study Registration Dates

• First Submitted: September 10, 2018
• First Submitted That Met QC Criteria: September 17, 2018
• First Posted (Actual): September 19, 2018

Study Record Updates

• Last Update Posted (Actual): February 5, 2020
• Last Update Submitted That Met QC Criteria: February 4, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Urination Disorders; Elimination Disorders; Urinary Incontinence; Enuresis; Urinary Incontinence, Stress
• Other Study ID Numbers: SPD16-001-00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No